3 Companies Raising Guidance This Earnings Season
BWX Technologies (BWXT), Johnson & Johnson (JNJ), and UnitedHealth Group (UNH) raised FY26 guidance following strong quarterly results. BWXT reported 18% revenue growth and raised EPS guidance to $4.70–$4.80. JNJ saw 5.9% sales growth and increased EPS outlook to $11.10. UNH improved cost trends and raised EPS guidance to at least $20.50.
How this was made
The 30-second read
Why it matters
Each company’s guidance increase provides a concrete earnings-estimate revision catalyst, with the article emphasizing drivers (commercial nuclear demand, Innovative Medicine growth, and improving medical cost trends).
Market read
Guidance raises at large-cap healthcare issuers typically drive near-term estimate revisions and sentiment, especially when tied to measurable operating metrics.
What to watch
For UNH, membership declines remain a stated headwind; for JNJ, MedTech growth is described as softer, which could cap upside despite EPS gains.
Background
The article frames three healthcare large caps as having raised FY26 outlooks following quarterly results, highlighting specific EPS and cash-flow or cost-metric changes.
Ticker impact
BWX Technologies raised FY26 adjusted EPS guidance to $4.70–$4.80 and free cash flow to $345–$360 million after strong quarterly results.
Likely upward pressure as the market reprices FY26 earnings and cash-flow expectations.
The article provides specific, company-issued FY26 guidance increases and links them to reported revenue and commercial operations strength.
Johnson & Johnson increased FY26 adjusted EPS outlook to $11.10 and raised expected annual sales to $101.2B at the midpoint.
Likely positive bias as investors price in the higher FY26 EPS and sales trajectory.
The piece states explicit FY26 guidance changes and ties them to Innovative Medicine growth and portfolio strength.
UnitedHealth Group raised FY26 adjusted EPS outlook to at least $20.50 after a lower medical care ratio and higher operating earnings.
Likely upward repricing as the market focuses on the improved medical cost outlook and higher FY26 EPS floor.
The article includes concrete FY26 EPS guidance and cost-metric improvement, but it is a multi-name roundup so incremental novelty may be limited.
Market effects
Positive guidance across defense nuclear, pharma/medtech, and managed care can lift sentiment toward healthcare earnings durability.
Primarily US large-cap healthcare sentiment; limited direct cross-region transmission implied.
Healthcare guidance strength can modestly support global risk appetite for defensive growth within developed markets.
Counterpoint
Guidance raises may already be partially anticipated after “solid quarterly results,” so price reaction could be muted if expectations were high.
Key entities
- public_companyBWX Technologies
Raised FY26 adjusted EPS guidance and free cash flow outlook after strong quarterly performance.
- public_companyJohnson & Johnson
Raised FY26 adjusted EPS and sales outlook, citing Innovative Medicine strength.
- public_companyUnitedHealth Group
Raised FY26 adjusted EPS outlook, citing improved medical care ratio and operating earnings.
